ReviewInfectious diseases and therapy2022
Coccidioidomycosis: A Contemporary Review.
Review in Infectious diseases and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Skeletal coccidioidomycosis: an atypical pediatric presentation.Skeletal radiology · 2026Article
- Pulmonary Coccidioidomycosis Linked to Shipping Containers, Taiwan, 2025.Emerging infectious diseases · 2026Article
- Coccidioidomycosis Testing Among Patients Hospitalized With Community-Acquired Pneumonia.Open forum infectious diseases · 2026Article
- Genetic and transcriptomic determinants of disseminated coccidioidomycosis identify a founder variant inmedRxiv : the preprint server for health sciences · 2026Article
- Dual activation of NLRP3 and pyrin inflammasomes mediates host responses to the human fungal pathogen Coccidioides.Nature communications · 2026Article
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
- First endogenous case ofJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Disseminated Coccidioidomycosis and Coccidioidal Meningitis Hospitalization, Texas, USA, 2016-2023Emerging infectious diseases · 2026Observational
- Coccidioidomycosis as a Diagnostic Consideration: Expanding the Pulmonary Differential.Cureus · 2026Article
- Empowering fungal infection research with single-cell RNA sequencing.Communications biology · 2026Review
- Neonatal management and outcomes in the setting of disseminated coccidioidomycosis in pregnancy.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Predicting Valley Fever Outbreaks: Novel Mechanistic Models Incorporating Climate and Ecological Interactions.bioRxiv : the preprint server for biology · 2026Article
- Coccidioidomycosis in Thailand: a diagnostic challenge in a non-endemic country.BMJ case reports · 2026Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- The Fungus Among Us: Latency, Reactivation, and the Expanding Clinical Spectrum of Coccidioidomycosis.Cureus · 2026Review
- Community-level Health and Socioeconomic Disparities in Coccidioidomycosis: Insights from the Social Deprivation and Healthy Places Indices.Medical mycology · 2026Article
- Rising burden of severe pediatric coccidioidomycosis: a 25-year single-center study.Journal of the Pediatric Infectious Diseases Society · 2026Observational
- Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi.Antimicrobial agents and chemotherapy · 2026Review
- Immunocompetent host and mortality-related coccidioidomycosis: A case report and narrative review.Medical mycology case reports · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coccidioidomycosis, colloquially known as Valley Fever, is an invasive dimorphic fungal infection caused by Coccidioides immitis and C. posadasii. The fungi are found in the arid desert soils of the southwestern US, as well as in parts of Mexico and Central and South America. Acquisition is typically via inhalation of arthroconidia which become airborne after both natural (e.g., earthquakes, dust storms, and fires) and human-related events (e.g., military maneuvers, recreational activities, agriculture, and construction). The incidence of infection in increasing likely a result of both climatic and populational changes. Further, the recognized geographic distribution of Coccidioides spp. is expanding, as cases are being diagnosed in new areas (e.g., eastern Washington, Oregon, and Utah). Most coccidioidal infections are asymptomatic (60%); however, approximately one-third develop a pulmonary illness which is a leading cause of community-acquired pneumonia in highly endemic areas. Uncommonly (0.5-2% of cases), the infection disseminates to extrapulmonary locations (e.g., skin, bones/joints, and the central nervous system), and is most commonly seen among persons with cellular immunodeficiencies (e.g., transplant recipients, HIV, and pregnancy) and non-Caucasian races (especially African Americans and Filipinos). The diagnosis of coccidioidomycosis requires astute clinical suspicion and laboratory findings, including positive serology, cultures, and/or histopathology results. Treatment is warranted among persons with pneumonia who have risk factors for complicated disease and among those with extrapulmonary disease. Novel antifungals with improved fungicidal activity and rapidity of action with fewer side effects and drug interactions are needed. Preventive strategies (e.g., education regarding the disease, dust avoidance, mask wearing, including among select groups, antifungal prophylaxis, and surveillance laboratory testing) are advised for residents and travelers to endemic areas. Currently, no preventive vaccine is available. Coccidioidomycosis has been recognized for over a century, and an expanding wealth of knowledge has been gained regarding this emerging infectious disease which will be reviewed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.